Why Morgan Joseph Expects Triple-Digit Gains For This Pfizer Partner

Mon, 03/05/2012 - 15:39 EDT - Seeking Alpha

By Takeover Analyst:Lpath (LPTN.OB), the leader of lipidomic-based therapeutics, is one of Morgan Joseph's top biotech picks - and for good reason. The company has several catalysts in play that address - and possibly cure - unmet medical needs. Developing monoclonal antibodies to target bioactive lipids through its ImmuneY2 platform technology, Lpath is, in my view, easily on Pfizer's (PFE) takeover radar. Here's why Morgan Joseph believes the company will hit $8 in less than 18 months from now:Lpath's lead product, iSONEP targets sphingosine 1 phosphate (S1P) to treat wet AMD (age-related macular degeneration), RPE (retinal pigment epithelium) detachment, and diabetic retinopathy. Around 50% of the elderly, or 1.5M in the United States, suffer from a condition in which blood vessels grow in the back of the eye to create a leaky faucet. Currently available drugs Lucentis and Avastin, owned by Genentech of the Roche Group (RHHBY.PK), only treat the symptomsComplete Story »

Original article
Login or register to post comments

Why Lpath Shares Could Soar Ahead Of ISONEP Trial
By LastFinancier: San Diego-based Lpath, Inc. (LPTN.OB) is the leader in the discovery and development of monoclonal antibodies targeted to bioactive lipids. Lpath derives its unique position from its proprietary ImmuneY2TM platform - a drug-discovery process that generates antibodies against bioactive lipids.
Age-Related Macular Degeneration: A Promising Investment Opportunity
By Cris Frangold: Macular degeneration is one of the most debilitating age-related degenerative medical conditions. It results in the loss of vision leading to difficulty in reading or recognizing faces. The condition worsens with age if not treated effectively.
Lpath: The Leader In Lipidomics
By Alpha Cardinal:Lpath: The Leader in LipidomicsJu Lu, Ph.D., Mei-Hsin Cheng, Luke J. LeeLpath Inc. (LPTN) is an early-stage biotechnology firm focusing on the discovery and development of monoclonal antibodies targeting bioactive lipids. In the current landscape saturated with protein-centric drug development efforts, Lpath stands out as a category leader in the field of lipidomics.
Genentech/Roche in Uncomfortable Position Over Avastin
Derek Lowe submits: The Genentech/Roche (RHHBY.PK) drug Avastin has been in the news a lot lately, mostly about cost/benefit analysis for
LPath Investors Have iSONEP Trial Results In Sight
By Steven Breazzano:Upcoming events: PEDigree phase Ib/2a preliminary data late Q1 2012 or early Q2 2012
Avastin and Lucentis: Roche's Quandry
Pharmalot submits: The results of an eagerly anticipated clinical trial are leaking out and early indications are that the Avastin cancer med is about as effective as Lucentis in treating a form of age-related macular degeneration, The New York Times writes.
Lpath Back In Play
By Brian L. Wilson:It's time to start tracking Lpath (LPTN.OB) again. The San Diego-based pharmaceutical company is leading a new trend of lipid-based therapies and shares are once again on the rise as speculators begin to watch their drug portfolio and rumors of a takeover by pharmaceutical giant Pfizer (PFE) begin to re-surface.
LPath, Inc.: Multiple Phase 2 Trials and Pfizer Partnership Provide Path to Profits
Steven Breazzano submits:Upcoming events: PEDigree Phase Ib/2a preliminary data Q4 2011 and additional Phase 2 trial data 2012.
Genentech Offers Secret Rebate for AMD Drug: In the Patient’s Best Interest?
Pharmalot submits: In an effort to promote Lucentis for treating age-related macular degeneration, Roche’s (RHHBY.PK) Genentech is offering a confidential rebate to retinal specialists who may otherwise use Avastin, which is another med sold by the same biotech. Why bother? Avastin is not approved to treat AMD, but many docs believe it is equally effective.
Roche, the Professor and Washington Lobbying
Pharmalot submits: Earlier this week, the long-awaited results of a head-to-head trial comparing two different drugs marketed by Roche’s (RHHBY.PK) Genentech unit were leaked. The upshot? The older Avastin cancer med is about as effective as Lucentis in treating a form of age-related macular degeneration. The significance? Avastin is not approved to treat the eye afflication, but is widely used off-label and costs up to $50 injection.

Main menu

Secondary menu

Why Morgan Joseph Expects Triple-Digit Gains For This Pfizer Partner

Related

Latest

User login

Our Blog

Markets Map

Follow Us

Secondary menu